Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection28-11-2022
28-11-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Famotidine Injection23-11-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Certificate / Duplicate Share Certificate17-11-2022
Zydus Lifesciences Ltd - 532321 - Transcript
Transcript of Investor Call held on November 11, 202216-11-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients16-11-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / half year ended on September 30, 2022 in Financial Express on November 12, 2022.12-11-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the investor call on financial results for the quarter / half year ended on September 30, 202211-11-2022
Q2FY23 Quarterly Result Announced for Zydus Lifesciences Ltd.
Pharmaceutical company Zydus Lifesciences announced Q2FY23 results: Q2FY23: Reported revenue from Operations at Rs 41,347 million, up 10% over last year. Adjusting for COVID-related revenues in last year’s base, growth was 15% YoY. Research & Development (R&D;) investments for the quarter stood at Rs 2,534 million (6.1% of revenues). Reported EBITDA for the quarter was Rs 8,153 million, down 9% YoY. The reported EBITDA margins for the quarter stood at 19.7%. Adjusted for COVID-related inventory provision, the EBITDA margins stood at 22.6% of revenues. The reported net profit for the quarter was Rs 5,225 million. Adjusted for inventory provision, exceptional items and profit/ (loss) from discontinued operations, net profit for the quarter was down 9% YoY. Capex (organic) for the quarter was Rs 2,157 million H1FY23: Reported Revenue from operations at Rs 82,074 million, up 6% over last year. Adjusting for COVID-related revenues in last year’s base, growth was 13% YoY. R&D; investments for the half year stood at Rs 5,376 million (6.6% of revenues). Reported EBITDA for the half year was Rs 16,483 million, down 12% YoY. The reported EBITDA margin for the half-year stood at 20.1%. Adjusted for COVID-related inventory provision, the EBITDA margins stood at 21.5% of revenues. The reported net profit for the half year was Rs 10,408 miilion. Adjusted for inventory provision, exceptional items and profit/ (loss) from discontinued operations, net profit for the half year was down 10% YoY. Capex (organic) for the half year was Rs 4,985 million. Our Q2 FY23 performance reflects strong execution in our key businesses, sustaining growth momentum and profitability. While new launches including gRevlimid aided US growth, India Formulations continued to deliver double-digit growth, excluding COVID-related revenues. We expect to improve our profitability steadily going ahead, and remain on track to deliver 20% plus EBITDA margins for the current fiscal. We are delighted with the resolution of regulatory issues at Moraiya and remain committed to enhancing quality and compliance standards across our manufacturing network, said Sharvil Patel Result PDF11-11-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter / half year ended on September 30, 202211-11-2022